Product
Supplier
Encyclopedia
Inquiry
Home > News > Pharma News > Medicare Payment: Grass-roots co-ordinated payment

Medicare Payment: Grass-roots co-ordinated payment

ECHEMI 2019-10-22

medical-code

At 10 a.m. on October 9, the Information Office of the State Council held a regular briefing on the policies of the State Council. Chen Jinfu, deputy director of the State Medical Security Bureau, and the relevant person in charge of the State Health and Health Commission were invited to introduce the situation of improving the medication guarantee mechanism of hypertension and diabetes outpatient clinics for urban and rural residents, and to answer the reporters'questions.

Chen Jinfu, introducing the implementation of the Guiding Opinions on Improving Medication Guarantee Mechanisms for Outpatients with Hypertension and Diabetes among Urban and Rural Residents (hereinafter referred to as "Opinions") by the State Medical Insurance Bureau in conjunction with the Ministry of Finance, the Health Care Commission and the Drug Administration at the 64th Standing Meeting of the State Council, said that he would improve the medication guarantee policies for out Measures should be taken to improve and upgrade the security treatment, target, scope and level, make full use of "payment lever" to regulate drug supply and ensure fund balance. There is no doubt that the increase of medical insurance treatment means the increase of investment and the increase of security function and fund expenditure. In this regard, Chen Jinfu emphasized that on the basis of medication guarantee in the "two diseases" clinic of medical insurance, the payment standard should be improved, the payment mode should be reformed, the drug recruitment system should be reformed, the medical service should be standardized, and the "combination boxing" should be used to control and reduce costs. Outpatient expenses overall payment of antihypertensive and hypoglycemic drugs "four priorities" National Medical Security Bureau and other nine departments have issued "Opinions on the implementation of the pilot expansion of regional scope of centralized drug procurement and use by state organizations" recently, clearly promoting the centralized drug procurement and use pilot centralized drug procurement model nationwide. It will enable qualified medical institutions throughout the country to provide high-quality and low-cost pilot medicines, and further reduce the burden of drug use among the masses.

Obviously, priority to centralize purchasing varieties, priority to consistency evaluation of generic drugs, priority to medical insurance catalogue varieties and essential drugs varieties has become a major trend in China's pharmaceutical market at this stage. This press conference, focusing on the hypertension and diabetes "two diseases" diagnosis and treatment services and drug supply work to make a coordinated deployment, is bound to have seen in the centralized procurement work in the key areas of chronic disease price and cost pressures, as well as the objective long-term drug burden of clinical patients. According to the data of intranet, the sales of antihypertensive drugs in chemical terminal of public hospitals in key provinces and municipalities have increased year by year in recent years, with the market scale reaching 7.801 billion yuan in 2018, an increase of 4.51% over the previous year. The total sales of Top 10 products amounted to 4.28 billion yuan, accounting for 54.87% of the total market of antihypertensives. The diabetes drug market has also expanded year by year, reaching 6.768 billion yuan in 2018, an increase of 7.49% over the previous year. In terms of competition pattern, Top 10 sales totaled 4.341 billion yuan, accounting for 64.14% of the total diabetes drug market. The executive meeting of the State Council convened just a month ago to discuss and decide on the policy of reimbursement of medicines for hypertension and diabetes outpatients in urban and rural areas.

Disclaimer: ECHEMI reserves the right of final explanation and revision for all the information.

Looking for chemical products? Let suppliers reach out to you!

Comment
Comment
  • Life Science Ingredients Industry Overview

    This issue offers a deep exploration of the evolving pharmaceutical and nutrition landscape, combining data, analysis, and insight to reveal key industry shifts and emerging directions. Support online permanent download.
    Published in: Nov. 2025

Trade Alert

Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)

Scan the QR Code to Share

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.